A bipolar mania therapy demonstrated statistically significant placebo-adjusted improvements at Week 3, with YMRS up 3.1 points (p=0.045) and CGI-BP Severity of Mania up 0.4 points (p=0.024). Meeting both primary and secondary endpoints could de-risk the program and prompt further Phase II/III discussions, potentially supporting near-term investor interest.
BTIG raised Rapport Therapeutics' price target to $75 from $65, while maintaining a Buy rating. With RAPP near $42.68, the move implies substantial near-term upside if the target proves achievable. The catalyst could spark a rally in the name, contingent on corroboration from peers and upcoming trial or data-related milestones.